Phagelux Of China Raises Funds From WuXi PharmaTech Co., Ltd.

Published: Mar 06, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

March 6, 2014 -- Shanghai-based PhageLux has received an investment from WuXi PharmaTech Healthcare Fund, the investment arm of CRO WuXi PharmaTech. PhageLux uses phages to solve bacterial problems in fields such as crop disease, animal health, food safety and general sanitary. This year, PhageLux will begin work on human health issues. PhageLux has taken offices in the ChinaBio® Accelerator located in the Biotech VC Plaza at Shanghai’s Zhangjiang Hi-Tech Park. More details....

Stock Symbol: (NYSE: WX)

Help employers find you! Check out all the jobs and post your resume.

Back to news